Effect of vitamin D supplements on relapse rate and Expanded Disability Status Scale (EDSS) in multiple sclerosis (MS): a systematic review and meta-analysis.

سال انتشار: 1398
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 353

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

MSC16_049

تاریخ نمایه سازی: 11 آذر 1398

چکیده مقاله:

Background: Multiple sclerosis is an inflammatory disease while there are controversies regarding the role of vitamin D supplements in controlling relapse and disability improvement during treatment.Objective: The goal of this systematic review and meta-analysis was to evaluate the effect of vitamin D supplements on MS related relapse and Expanded Disability Status Scale (EDSS) Methods: We searched databases to include randomized clinical trials (RCTs) which were published up to October 2018. We included RCTs, being single-blinded or double-blinded or open-label trials in which one of the main outcomes was EDSS and/ or relapse after vitamin D supplementation. All statistical analyses were performed using RevMan 5.3. Odds ratios (OR) and95% confidence intervals (95% CI) were calculated for relapse between treatment arms..Mean difference was calculated for EDSS comparisons.Results: Nine articles were included for analysis.Of these 9 studies, five compared vitamin D supplement groups with placebo (group 1 studies) and 4 compared high and low dose vitamin D groups. There was a total of 561 patients analyzed. Being treated with vitamin D instead of placebo showed no effect on relapse rate(OR=0.66, 95% CI=0.28-1.54) as well as EDSS (mean difference=0.06, 95%CI (-0.31, 0.42)). The results of studies comparing high vs. low vitamin D interventions showed no significant effect on relapse rate (OR=1.08, 95%CI(0.29-4.08) as well as final EDSS (mean difference=0.17, 95%CI= -0.73, 1.07)..Conclusion: Our findings show that vitamin D supplements (high or low dose) have no significant effect on relapse rate and disability during treatment in MS patients.

نویسندگان

Amirreza Azimi,

MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences,Tehran, Iran.

Sara Hanaei,

Research Center for Immunodeficiencies (RCID), Tehran University of Medical Sciences (TUMS), Tehran, Iran/Universal Scientific Education and Research Network (USERN), Tehran, Iran

Mehdi Mohammadifar,

Department of Radiology, Zanjan university of medical sciences

Sreeram V Ramagopalan,

Bristol-Myers Squibb, Uxbridge, United Kingdom

Mahsa Ghajarzadeh,

Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran

Mahsa Ghajarzadeh,

Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran